PHARMACOLOGICAL EVALUATION OF TWO NOVEL ANALOGUES OF MIANSERIN: 2-N-CARBOXAMIDINONORMIANSERIN(FCC5) AND 2-N-CARBOXAMIDONORMIANSERIN (FCC13)
Autor: | Ian M. Leitch, Mary P. Rechtman, Andrew Rawlow |
---|---|
Rok vydání: | 1992 |
Předmět: |
Central Nervous System
Male Serotonin medicine.medical_specialty Physiology Bronchoconstriction Guinea Pigs Withdrawal reflex Blood Pressure Mianserin Histamine H1 receptor Pharmacology Catalepsy Mice Physiology (medical) Internal medicine Fenfluramine Reflex medicine Animals Edema Decerebrate State Morphine Chemistry Antagonist Rats Inbred Strains Biological activity medicine.disease Rats Endocrinology Histamine H1 Antagonists Female Serotonin Antagonists medicine.symptom Antagonism medicine.drug |
Zdroj: | Clinical and Experimental Pharmacology and Physiology. 19:25-30 |
ISSN: | 1440-1681 0305-1870 |
DOI: | 10.1111/j.1440-1681.1992.tb00393.x |
Popis: | 1. The pharmacological properties have been examined of FCC5 (2-N-carboxamidinonormianserin) and FCC13 (2-N-carboxamidonormianserin), two novel analogues of mianserin. 2. FCC5 or FCC13 (100 micrograms/kg, i.v.) caused long-lasting (greater than 1 h) abolition of 5-hydroxytryptamine (5-HT) and histamine-induced bronchoconstriction in the anaesthetized guinea-pig. Both analogues had no effect (up to 1 mg/kg, i.v.) on bronchoconstriction caused by acetylcholine (25-50 micrograms/kg, i.v.). 3. The pressor effects of 5-HT in pithed rats were significantly attenuated by FCC5 (0.1 mg/kg, i.v.) or FCC13 (0.5 mg/kg, i.v.). 4. Oedema in the rat hind paw caused by intraplantar 5-HT was inhibited by FCC5 (ID50 0.76 mg/kg, i.p.; 2.7 mg/kg, p.o.) or FCC13 (ID50 0.65 mg/kg, i.p.; 5.8 mg/kg, p.o.). 5. In the central nervous system (CNS), FCC13 caused antagonism of 5-HT activity. It inhibited: (i) L-5-hydroxytryptophan (L-5-HTP)-induced head twitches in mice (ID50 1.85 mg/kg, i.p.), (ii) fenfluramine-induced facilitation of flexor reflex activity (FRA) in spinalized decerebrate rats (SDR) (IC50 0.57 mg/kg, i.p.). 6. FCC5 (less than or equal to 30 mg/kg, i.p. and less than or equal to 3 mg/kg, i.p., respectively) had no effect in either test. In contrast to mianserin, it also had no overt central actions as (less than or equal to 30 mg/kg, i.p.) had no effect on: (i) morphine-induced catalepsy (MIC) or (ii) clonidine-induced facilitation of FRA in SDR. However, high doses of FCC13 inhibited MIC (ID50 20 mg/kg, i.p.), but had no effect on (ii) (less than or equal to 10 mg/kg, i.p.). 7. Thus, FCC5 and FCC13 are potent, orally active H1 and 5-HT receptor antagonists. However, in contrast to FCC13 and mianserin, FCC5 did not cause CNS-mediated effects. |
Databáze: | OpenAIRE |
Externí odkaz: |